Published in Eur J Gastroenterol Hepatol on July 01, 2015
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Inflammatory bowel disease: cause and immunobiology. Lancet (2007) 6.07
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.83
Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther (2014) 3.74
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 2.91
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Prophylaxis and treatment of infective endocarditis in adults: a concise guide. Clin Med (2005) 2.88
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc (2006) 2.73
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut (2011) 2.58
Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther (2010) 2.12
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 1.95
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol (2012) 1.73
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2008) 1.58
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol (2010) 1.54
Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol (2011) 1.41
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis (2009) 1.25
A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol (2010) 1.22
Treatment of inflammatory bowel disease (IBD). Pharmacol Rep (2011) 1.20
Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther (2008) 1.15
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther (2010) 1.14
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther (2009) 1.13
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess (2011) 1.09
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis (2012) 1.08
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther (2009) 1.06
Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther (2010) 1.04
Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment Pharmacol Ther (2014) 1.01
Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther (2007) 0.98
Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf (2008) 0.97
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol (2009) 0.90
The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther (2007) 0.87
Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol (2011) 0.83
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis (2012) 0.81
Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci (2012) 0.81
Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol (2011) 0.79
What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol (2014) 0.79
Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series. Rev Esp Enferm Dig (2011) 0.79
Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol (2010) 0.78
Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis (2010) 0.78
Elective switching from infliximab to adalimumab in stable Crohn's disease. Inflamm Bowel Dis (2013) 0.76